Physician profile
Derrick E Anderson
NPI 1609876606
$1,312.17
in general payments reported to CMS, 2019-2025
26 companies · $429 in 2025
The $429 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $27.06 · 2021: $101 · 2022: $248 · 2023: $374 · 2024: $133 · 2025: $429.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $936.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $935.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $234.83 | 2022-2025 | Vraylar, Qulipta, Viberzi |
| Glaxosmithkline, LLC. | $142.70 | 2019-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals Lp | $117.04 | 2022-2025 | Breztri, Airsupra, Farxiga |
| Novo Nordisk INC | $116.42 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $101.31 | 2021 | |
| Janssen Pharmaceuticals, INC | $94.66 | 2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $70.92 | 2022 | |
| Lilly USA, LLC | $64.26 | 2022-2025 | Mounjaro, Zepbound |
| Ironwood Pharmaceuticals, INC | $45.33 | 2023 | Linzess |
| Exact Sciences Corporation | $41.24 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.35 | 2022-2023 | Jardiance |
| Amgen INC. | $30.32 | 2024 | Repatha, Otezla |
| Ani Pharmaceuticals, INC. | $27.98 | 2025 | Purified Cortrophin Gel |
| Neurocrine Biosciences, INC. | $25.95 | 2024 | Ingrezza |
| Ionis Pharmaceuticals, INC. | $18.52 | 2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $16.40 | 2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $15.50 | 2023 | |
| Horizon Therapeutics Plc | $15.45 | 2023 | Krystexxa |
| Paratek Pharmaceuticals, INC. | $15.39 | 2022 | |
| Edwards Lifesciences Corporation | $14.52 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Redhill Biopharma INC. | $13.89 | 2022 | |
| Gilead Sciences, INC. | $13.81 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $13.36 | 2022 | |
| Cranial Technologies, INC | $13.12 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.90 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derrick Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.